1Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer[J].J Clin Oncol,2000,18(1):136
2André T, Bensmaine MA, Louvet C, et al. Multicenter phaseⅡstudy of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen[J]. J Clin Oncol, 1999,1
3Woynarowski JM, Faivre S, Herzig MC, et al. Oxaliplatin-induced damage of cellular DNA[J]. Mol Pharmacol, 2000,58(5):920
4Massari C, brienza S, Rotarski M, et al. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function[J]. Cancer Chemother Pharmacol, 2000,45:157
5Levi F, Metzger G, Massari C, et al. Oxaliplatin: pharmacokinetics and chronopharmacological aspects[J].Clin Pharmacokinet,2000,38(1):1
6de Jongh FE, van Veen RN, Veltman SJ, et al. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients[J]. Br J Cancer,2003,88(8):1199
7Alliot C, Messouak D, Beets C, et al. Severe anaphylactic reaction to oxaliplatin[J]. Clin Oncol (R Coll Radiol),2001,13(3):236
8de Gramont A, Figer A, Seymour M, et al .Leucovorin and fluorouracil with or without oxaliplatin as first -line treatment in advanced colorectal cancer[J]. J Clin Oncol ,2000,18(16):2938
9Taieb S, Trillet-Lenoir V, Rambaud L,et al. Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients[J]. Cancer, 2002 ,94(9):2434
10Grolleau F,Gamelin L, Boisdron-Celle M, et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels[J]. J Neurophysiol, 2001,85(5):2293
2Mita C,Chatelut E,Bekradda M, et al. Phase I and pharmacological study of an oxaliplatin and carboplatin combination in advanced malignancies[J]. Ann Oncol, 2003,14( 12):1776.
3Elias D,Bonnay M,Puizillou JM, et al. Heated intra-operative intraperitoneal Oxaliplitin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution[J]. Ann Oncol, 2002,13(2):267.
